Mouse CD30 Ligand/TNFSF8 Antibody

Catalog #: AF732 Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
AF732
AF732-SP

IL‑6 Secretion Induced by CD30 Ligand/TNFSF8 and Neutralization by Mouse CD30 Ligand/TNFSF8 Antibody.

1 Image

Product Details

Supplemental Products

Reviews

Summary Data Examples Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Mouse CD30 Ligand/TNFSF8 Antibody Summary

Species Reactivity

Mouse

Specificity

Detects mouse CD30 Ligand/TNFSF8 in direct ELISAs and Western blots. In direct ELISAs and Western blots, approximately 5% cross‑reactivity with recombinant human CD30 Ligand is observed.

Source

Polyclonal Goat IgG

Purification

Antigen Affinity-purified

Immunogen

Mouse myeloma cell line NS0-derived recombinant mouse CD30 Ligand/TNFSF8
Gln68-Asp239
Accession # P32972

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Endotoxin Level

<0.10 EU per 1 μg of the antibody by the LAL method.

Applications

Recommended Concentration

Sample

Western Blot

0.1 µg/mL

Recombinant Mouse CD30 Ligand/TNFSF8 (Catalog # 732-CL)

Neutralization

Measured by its ability to neutralize CD30 Ligand/TNFSF8-induced IL‑6 secretion in the HDLM human Hodgkin’s lymphoma cell line. The Neutralization Dose (ND₅₀) is typically 3-10 µg/mL in the presence of 500 ng/mL Recombinant Mouse CD30 Ligand/TNFSF8 and 10 µg/mL of a cross-linking antibody, Mouse polyHistidine Monoclonal Antibody.

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Neutralization

View Larger

IL‑6 Secretion Induced by CD30 Ligand/TNFSF8 and Neutralization by Mouse CD30 Ligand/TNFSF8 Antibody. In the presence of a cross-linking antibody, Mouse polyHistidine Monoclonal Antibody (10 µg/mL, Catalog # MAB050), Recombinant Mouse CD30 Ligand/TNFSF8 (Catalog # 732-CL) stimulates IL-6 secretion in the HDLM human Hodgkin’s lymphoma cell line in a dose-dependent manner (orange line), as measured by the Human IL-6 Quantikine ELISA Kit (Catalog # D6050). Under these conditions, IL-6 secretion elicited by Recombinant Mouse CD30 Ligand/TNFSF8 (500 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Mouse CD30 Ligand/TNFSF8 Antigen Affinity-purified Poly-clonal Antibody (Catalog # AF732). The ND₅₀ is typically 3-10 µg/mL.

Reconstitution Calculator

Preparation and Storage

Reconstitution

Reconstitute at 0.2 mg/mL in sterile PBS.

Shipping

The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: CD30 Ligand/TNFSF8

CD30 Ligand (CD30L)/TNFSF8 is a type II membrane protein belonging to the TNF superfamily. CD30L is expressed on the cell surface of activated T cells, B cells, and monocytes. The protein is also constitutively expressed on granulocytes and medullary thymic epithelial cells. The specific receptor for CD30L is CD30/TNFRSF8, a type I transmembrane glycoprotein belonging to the TNF receptor superfamily. CD30 was originally identified as a cell surface antigen of Hodgkin's and Reed-Sternberg cells using the monoclonal antibody Ki-1. CD30 is also expressed on different non-Hodgkin's lymphomas, virus-infected T and B cells, and on normal T and B cells after activation. Among T cells, CD30 is preferentially expressed on a subset of T cells producing Th2-type cytokines and on CD4⁺/CD8⁺ thymocytes that coexpress CD45RO and IL-4 receptor. CD30 ligation by CD30L mediates pleiotropic effects including cell proliferation, activation, differentiation and cell death by apoptosis. CD30 can act as a co‑stimulatory molecule in thymic negative selection and may also play a critical role in the pathophysiology of Hodgkin's disease and other CD30⁺ lymphomas.

References

Brunangelo, F. et al. (1995) Blood 85:1.
Gruss, H-J. and F. Herrmann (1996) Leukemia and Lymphoma 20:397.
Chiarle, R. et al. (1999) J. Immunol. 163:194.

Entrez Gene IDs

944 (Human); 21949 (Mouse)

Alternate Names

CD153 antigen; CD153; CD30 antigen ligand; CD30 Ligand; CD30L; CD30-L; CD30LCD30 ligand; CD30LGMGC138144; TNFSF8; tumor necrosis factor (ligand) superfamily, member 8; tumor necrosis factor ligand superfamily member 8